UY33578A - PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS - Google Patents

PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS

Info

Publication number
UY33578A
UY33578A UY0001033578A UY33578A UY33578A UY 33578 A UY33578 A UY 33578A UY 0001033578 A UY0001033578 A UY 0001033578A UY 33578 A UY33578 A UY 33578A UY 33578 A UY33578 A UY 33578A
Authority
UY
Uruguay
Prior art keywords
peptide
complex
integrine
joins
involve
Prior art date
Application number
UY0001033578A
Other languages
English (en)
Inventor
Dr Carsten Corvey
Cameron Batrice
Dabdoubi Tarik
Decary Stephanie
Dr Nicolas Baurin
Papin David
Dr Christian Lange
Dr Horst Blum
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43618709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33578(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33578A publication Critical patent/UY33578A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a un péptido o complejo peptídico que se une a integrina a2, a uno o más ácidos nucleicos que codifican el péptido o complejo peptídico, una célula recombinante que produce el péptido o complejo peptídico, un método para producir el péptido o complejo peptídico, una composición farmacéutica que comprende el péptido o complejo peptídico o el ácido nucleico o los ácidos nucleicos para su uso como un medicamento, un método para detectar integrina a2 y un método de exploración.
UY0001033578A 2010-08-31 2011-08-29 PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS UY33578A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305929 2010-08-31

Publications (1)

Publication Number Publication Date
UY33578A true UY33578A (es) 2012-03-30

Family

ID=43618709

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033578A UY33578A (es) 2010-08-31 2011-08-29 PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS

Country Status (21)

Country Link
US (2) US9234039B2 (es)
EP (1) EP2611462B1 (es)
JP (2) JP6250395B2 (es)
KR (1) KR101853604B1 (es)
CN (1) CN103298488B (es)
AR (1) AR082805A1 (es)
AU (1) AU2011298369B2 (es)
BR (1) BR112013004124A2 (es)
CA (1) CA2809493A1 (es)
CL (1) CL2013000538A1 (es)
CO (1) CO6680702A2 (es)
IL (1) IL224950A (es)
MA (1) MA34475B1 (es)
MX (1) MX342171B (es)
MY (1) MY161268A (es)
NZ (2) NZ607720A (es)
RU (1) RU2588668C2 (es)
SG (1) SG187881A1 (es)
TW (1) TWI560199B (es)
UY (1) UY33578A (es)
WO (1) WO2012028622A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
US10501546B2 (en) 2015-09-04 2019-12-10 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
AU2021298222A1 (en) * 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies
CN112300282A (zh) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
CN112891523B (zh) * 2021-03-25 2023-07-04 遵义医科大学 猪带绦虫Ts14-3-3.3 DNA疫苗制备及鉴定方法
US12037361B2 (en) 2021-08-31 2024-07-16 The Hong Kong Polytechnic University Methods for treating multidrug resistant breast cancer
WO2023192489A2 (en) * 2022-03-30 2023-10-05 Adept Therapeutics Inc. Anti-adenosine receptor (a2ar) antibodies and the use thereof
WO2024001669A1 (zh) * 2022-06-27 2024-01-04 昱言科技(北京)有限公司 靶向itga2的抗体和包含此抗体的抗体药物缀合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20050281828A1 (en) * 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP1951757B1 (en) 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
PL1945665T3 (pl) 2005-10-21 2012-02-29 Genzyme Corp Leki oparte na przeciwciałach z ulepszoną aktywnością adcc
AU2006315037C1 (en) * 2005-11-18 2013-05-02 Ichnos Sciences SA Anti-alpha2 integrin antibodies and their uses
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
CN101443359A (zh) * 2006-03-16 2009-05-27 健泰科生物技术公司 Egfl7抗体及其使用方法
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US7994290B2 (en) 2007-01-24 2011-08-09 Kyowa Hakko Kirin Co., Ltd Effector function enhanced recombinant antibody composition
KR20090114449A (ko) 2007-02-14 2009-11-03 글락소 그룹 리미티드 Ｉｇｆ-ⅰｒ에 대한 항체
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2229410A4 (en) 2007-12-05 2012-07-04 Massachusetts Inst Technology AGLYCOSYLATED IMMUNOGLOBULIN MUTANTS
AU2009312532B2 (en) * 2008-11-06 2013-05-16 Ichnos Sciences SA Treatment with anti-alpha2 integrin antibodies
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
CA2753280C (en) * 2009-02-23 2017-04-25 Gene Techno Science Co., Ltd. Anti-human .alpha.9 integrin antibody and use thereof
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity

Also Published As

Publication number Publication date
AU2011298369A1 (en) 2013-03-21
JP2017043623A (ja) 2017-03-02
JP2013544489A (ja) 2013-12-19
IL224950A (en) 2017-05-29
EP2611462B1 (en) 2017-01-18
CN103298488A (zh) 2013-09-11
MA34475B1 (fr) 2013-08-01
MX342171B (es) 2016-09-19
JP6250395B2 (ja) 2017-12-20
CN103298488B (zh) 2017-07-18
AU2011298369B2 (en) 2014-07-31
KR101853604B1 (ko) 2018-05-03
TWI560199B (en) 2016-12-01
NZ607720A (en) 2015-03-27
CO6680702A2 (es) 2013-05-31
BR112013004124A2 (pt) 2016-07-19
US20130156786A1 (en) 2013-06-20
RU2588668C2 (ru) 2016-07-10
SG187881A1 (en) 2013-03-28
NZ629595A (en) 2016-02-26
WO2012028622A2 (en) 2012-03-08
US20160176970A1 (en) 2016-06-23
CA2809493A1 (en) 2012-03-08
EP2611462A2 (en) 2013-07-10
MY161268A (en) 2017-04-14
CL2013000538A1 (es) 2014-03-28
AR082805A1 (es) 2013-01-09
MX2013002313A (es) 2014-02-27
RU2013114368A (ru) 2014-10-20
WO2012028622A3 (en) 2012-07-05
KR20140008298A (ko) 2014-01-21
US9234039B2 (en) 2016-01-12
TW201305205A (zh) 2013-02-01

Similar Documents

Publication Publication Date Title
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CL2017002233A1 (es) Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
BR112014012789A2 (pt) agentes terapêuticos compreendendo sequências de aminoácidos de insulina
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ECSP12011577A (es) Produccion recombinante de péptidos
CL2016001405A1 (es) A peptide mixture
DOP2014000170A (es) Compuestos de imidazopirrolidinona
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
AR090352A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
BR112013000650A2 (pt) poliptídeos de fator ix e métodos de uso dos mesmos.
CR20120052A (es) Polipéptidos del factor ix modificados y usos de los mismos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CL2014001217A1 (es) Polinucleotido que codifica un polipeptido de neurotoxina que muestra una menor duracion del efecto biologico en un sujeto; vector; celula huesped; polipeptido codificado; metodo de fabricacion del polipeptido; anticuerpo que se une al polipeptido; y su uso.
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
BR112012011740A2 (pt) polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii
CO6561782A2 (es) Polipetidos factor viii-fc quimericos e hibridos y metodos de uso de los mismos
AR093578A1 (es) Metodos para la elaboracion de polipeptidos procesados proteoliticamente
BR112015021708A2 (pt) Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200821